sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Amiodarone, disopyramide, lidocaine
|
disopyramide
|
lidocaine
|
NONE
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s63
|
DDI-DrugBank.d270.s63.p2
|
Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
|
Sympathomimetic amines
|
reserpine
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s2
|
DDI-DrugBank.d389.s2.p0
|
Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
|
probenecid
|
phenylbutazone
|
NONE
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s0
|
DDI-DrugBank.d443.s0.p8
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Dilantin
|
Crixivan
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p305
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
oxcarbazepine
|
ziprasidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p942
|
Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
|
5-HT1B/1D agonists
|
AXERT
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s4
|
DDI-DrugBank.d299.s4.p2
|
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
|
theophylline
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s3
|
DDI-DrugBank.d284.s3.p11
|
Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
|
L-methionine
|
acetaminophen
|
EFFECT
|
L-Methionine_ddi.xml
|
DDI-DrugBank.d528.s0
|
DDI-DrugBank.d528.s0.p7
|
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
|
FLOLAN
|
antihypertensive agents
|
EFFECT
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s0
|
DDI-DrugBank.d241.s0.p1
|
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
|
fluoxetine
|
carvedilol
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s1
|
DDI-DrugBank.d269.s1.p17
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
verapamil
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p3
|
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
|
acetylsalicylic acid
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s2
|
DDI-DrugBank.d488.s2.p14
|
In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
|
Angiomax
|
heparin
|
EFFECT
|
Bivalirudin_ddi.xml
|
DDI-DrugBank.d569.s1
|
DDI-DrugBank.d569.s1.p0
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
encainide
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p6
|
In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
|
buspirone HCl
|
haloperidol
|
MECHANISM
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s3
|
DDI-DrugBank.d463.s3.p0
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
doxorubicin HCL
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p1
|
Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
|
dolasetron mesylate
|
atenolol
|
MECHANISM
|
Dolasetron_ddi.xml
|
DDI-DrugBank.d42.s5
|
DDI-DrugBank.d42.s5.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
magnesium
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p10
|
Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
|
Theophylline
|
theophylline
|
NONE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s27
|
DDI-DrugBank.d210.s27.p2
|
Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
|
Catecholamine-depleting drugs
|
beta-blocking agents
|
EFFECT
|
Acebutolol_ddi.xml
|
DDI-DrugBank.d388.s0
|
DDI-DrugBank.d388.s0.p1
|
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
|
CANCIDAS
|
carbamazepine
|
ADVISE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s14
|
DDI-DrugBank.d350.s14.p4
|
- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
|
propranolol
|
metoprolol
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s5
|
DDI-DrugBank.d521.s5.p13
|
Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
|
Aspirin
|
sulfinpyrazone
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s0
|
DDI-DrugBank.d443.s0.p5
|
Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
|
anticoagulants
|
Atromid-S
|
ADVISE
|
Clofibrate_ddi.xml
|
DDI-DrugBank.d12.s0
|
DDI-DrugBank.d12.s0.p0
|
Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
|
Anticholinergic agents
|
digoxin
|
MECHANISM
|
Dicyclomine_ddi.xml
|
DDI-DrugBank.d543.s4
|
DDI-DrugBank.d543.s4.p0
|
Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
|
Cimetidine
|
Cimetidine
|
NONE
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s2
|
DDI-DrugBank.d468.s2.p0
|
Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
|
Isocarboxazid
|
psychotropic agents
|
ADVISE
|
Isocarboxazid_ddi.xml
|
DDI-DrugBank.d108.s2
|
DDI-DrugBank.d108.s2.p0
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
sympathomimetics
|
antidiabetic drugs
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p13
|
Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
|
cinoxacin
|
caffeine
|
ADVISE
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s5
|
DDI-DrugBank.d562.s5.p2
|
Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
|
Edetate calcium disodium
|
zinc insulin
|
MECHANISM
|
Edetic Acid_ddi.xml
|
DDI-DrugBank.d191.s1
|
DDI-DrugBank.d191.s1.p7
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
Acetazolamide
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Astramorph
|
theophylline
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p932
|
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
|
ibuprofen
|
anticoagulants
|
ADVISE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s1
|
DDI-DrugBank.d415.s1.p9
|
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
|
NSAIDs
|
ACE-inhibitors
|
ADVISE
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s1
|
DDI-DrugBank.d219.s1.p0
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
phenothiazines
|
Type 1C antiarrhythmics
|
NONE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p16
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
ALPHAGAN P
|
barbiturates
|
ADVISE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p2
|
Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
|
Corticotropin
|
ACTH
|
NONE
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s2
|
DDI-DrugBank.d318.s2.p3
|
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
|
FLOLAN
|
vasodilators
|
EFFECT
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s0
|
DDI-DrugBank.d241.s0.p2
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
terfenadine
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p35
|
Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
|
vitamin A
|
acitretin
|
ADVISE
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s12
|
DDI-DrugBank.d353.s12.p8
|
An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
|
clonidine
|
neuroleptic
|
EFFECT
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s6
|
DDI-DrugBank.d224.s6.p0
|
propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were 20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
|
propranolol
|
propranolol
|
NONE
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s6
|
DDI-DrugBank.d81.s6.p1
|
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
|
Gleevec
|
erythromycin
|
ADVISE
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s0
|
DDI-DrugBank.d115.s0.p13
|
Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
|
Netilmicin
|
ethacrynic acid
|
ADVISE
|
Netilmicin_ddi.xml
|
DDI-DrugBank.d417.s0
|
DDI-DrugBank.d417.s0.p2
|
Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
|
naloxone
|
beta-endorphin
|
EFFECT
|
3155550.xml
|
DDI-MedLine.d63.s4
|
DDI-MedLine.d63.s4.p5
|
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
|
Barbiturates
|
quinidine
|
EFFECT
|
Hexobarbital_ddi.xml
|
DDI-DrugBank.d457.s0
|
DDI-DrugBank.d457.s0.p2
|
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.
|
amiodarone
|
macrolide antibiotics
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s59
|
DDI-DrugBank.d143.s59.p1
|
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
|
tricyclic antidepressants
|
methylphenidate
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s6
|
DDI-DrugBank.d238.s6.p0
|
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
|
anticonvulsant
|
Mefloquine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s11
|
DDI-DrugBank.d220.s11.p4
|
Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
thiazides
|
EFFECT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s11
|
DDI-DrugBank.d172.s11.p4
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
thiazides
|
EFFECT
|
Mefenamic acid_ddi.xml
|
DDI-DrugBank.d400.s6
|
DDI-DrugBank.d400.s6.p4
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
alcohol
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p35
|
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
|
fenofibrate
|
pravastatin
|
MECHANISM
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s13
|
DDI-DrugBank.d283.s13.p1
|
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
|
ciprofloxacin
|
isoniazid
|
NONE
|
Chlorpheniramine_ddi.xml
|
DDI-DrugBank.d235.s4
|
DDI-DrugBank.d235.s4.p18
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
amiodarone
|
ethacrynic acid
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p224
|
Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
|
Itraconazole
|
triazolam
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s11
|
DDI-DrugBank.d165.s11.p1
|
Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
|
celecoxib
|
lithium
|
INT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s6
|
DDI-DrugBank.d172.s6.p1
|
Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
|
CRIXIVAN
|
atazanavir
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s26
|
DDI-DrugBank.d97.s26.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
azole antifungals
|
erythromycin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p57
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
lincomycin
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p5
|
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
|
thioridazine
|
triflupromazine
|
NONE
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s21
|
DDI-DrugBank.d179.s21.p275
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
troleandomycin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p22
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
magnesium
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p24
|
and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
|
Videx
|
quinolones
|
MECHANISM
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s11
|
DDI-DrugBank.d427.s11.p1
|
Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
|
Fluvoxamine
|
MAOI
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s4
|
DDI-DrugBank.d76.s4.p1
|
Patients treated with Nalfon may be resistant to the effects of loop diuretics.
|
Nalfon
|
loop diuretics
|
EFFECT
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s10
|
DDI-DrugBank.d154.s10.p0
|
Adenosine effects are potentiated by dipyridamole.
|
Adenosine
|
dipyridamole
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s6
|
DDI-DrugBank.d226.s6.p0
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
anticoagulants
|
estrogens
|
NONE
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p10
|
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
|
carbamazepine
|
tricyclic antidepressant
|
EFFECT
|
11134454.xml
|
DDI-MedLine.d36.s2
|
DDI-MedLine.d36.s2.p0
|
Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
|
Indinavir
|
didanosine
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s37
|
DDI-DrugBank.d97.s37.p0
|
Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
|
tetracyclines
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s6
|
DDI-DrugBank.d488.s6.p11
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
methadone
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p11
|
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
|
steroidal anti-inflammatory agent
|
thiazide diuretics
|
EFFECT
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s25
|
DDI-DrugBank.d17.s25.p2
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
sirolimus
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p80
|
Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
|
cinoxacin
|
nonsteroidal anti-inflammatory agents
|
ADVISE
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s13
|
DDI-DrugBank.d562.s13.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
morphine
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p31
|
The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
|
nitroglycerin
|
vasodilators
|
EFFECT
|
Nitroglycerin_ddi.xml
|
DDI-DrugBank.d14.s0
|
DDI-DrugBank.d14.s0.p0
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
Videx
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p34
|
Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
|
phenytoin
|
esomeprazole
|
NONE
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s13
|
DDI-DrugBank.d29.s13.p8
|
Colchicine is inhibited by acidifying agents.
|
Colchicine
|
acidifying agents
|
MECHANISM
|
Colchicine_ddi.xml
|
DDI-DrugBank.d146.s0
|
DDI-DrugBank.d146.s0.p0
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
thiazides
|
estrogens
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p3
|
It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
|
isoniazid
|
acetaminophen
|
EFFECT
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s3
|
DDI-DrugBank.d187.s3.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
allopurinol
|
oxolinic acid
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p138
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
benzothiazepine
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p4
|
If a diuretic is also used, the risk of lithium toxicity may be increased.
|
diuretic
|
lithium
|
EFFECT
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s9
|
DDI-DrugBank.d561.s9.p0
|
These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
|
zalcitabine
|
lamivudine
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s7
|
DDI-DrugBank.d263.s7.p0
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
narcotics
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p5
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
tamoxifen
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p16
|
Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
|
epinephrine
|
halothane
|
EFFECT
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s5
|
DDI-DrugBank.d247.s5.p2
|
Therefore, diflunisal and INDOCIN should not be used concomitantly.
|
diflunisal
|
INDOCIN
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s2
|
DDI-DrugBank.d82.s2.p0
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
Antihistamines
|
CNS depressants
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p1
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
vitamin C
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p21
|
The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
|
catecholamines
|
Bretylium Tosylate
|
EFFECT
|
Bretylium_ddi.xml
|
DDI-DrugBank.d180.s1
|
DDI-DrugBank.d180.s1.p2
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
thiocyanate
|
diazepam
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p132
|
The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see a href= bupropz_od.htm#CI CONTRAINDICATIONS)
|
alcohol
|
WELLBUTRIN
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s26
|
DDI-DrugBank.d5.s26.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
azole antifungals
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p1
|
In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
|
methotrexate
|
L-glutamine
|
EFFECT
|
L-Glutamine_ddi.xml
|
DDI-DrugBank.d66.s6
|
DDI-DrugBank.d66.s6.p0
|
Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
|
aripiprazole
|
quinidine
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s15
|
DDI-DrugBank.d509.s15.p4
|
Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
|
diflunisal
|
acenocoumarol
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s0
|
DDI-DrugBank.d132.s0.p5
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
aspirin
|
ardeparin
|
EFFECT
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p14
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.